Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 3-Year FCF Growth Rate is 70.20% as of Jun. 2026, which is 35% above its 10-year median of 52.00. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 658 Drug Manufacturers companies, PRF Technologies ranks better than 93.31% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 70.20% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 60.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 8 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of PRF Technologies was 70.20% per year. The lowest was -86.60% per year. And the median was 52.00% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
PRF Technologies 3-Year FCF Growth Rate Related Terms
PRFX vs CTTH, UPC, AKAN: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where PRF Technologies's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 70.20% mean?
PRF Technologies (PRFX) has a 3-Year FCF Growth Rate of 70.20% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PRF Technologies and its competitors. This is 35% above median its historical median of 52.00. According to the industry distribution chart, PRF Technologies ranks #44 out of 658 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is PRF Technologies' 3-Year FCF Growth Rate too high?
PRF Technologies' current 3-Year FCF Growth Rate of 70.20% is 35% above median its 10-year median of 52.00. The Drug Manufacturers industry median 3-Year FCF Growth Rate is 9.15. PRF Technologies' value of 70.20% is 667.2% above this industry median. Based on the distribution chart, PRF Technologies ranks #44 out of 658 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' 3-Year FCF Growth Rate compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #44 out of 658 companies for 3-Year FCF Growth Rate. This places PRF Technologies in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 9.15. PRF Technologies' value of 70.20% is 667.2% above this benchmark. While the company's 10-year median is 52.00 vs. the industry median of 9.15, PRF Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 9.15, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PRF Technologies's current 3-Year FCF Growth Rate of 70.20% is 667.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for PRF Technologies and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 9.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current 3-Year FCF Growth Rate is 70.20%, which is 35% above median its own 10-year median of 52.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current 3-Year FCF Growth Rate of 70.20%. The current 3-Year FCF Growth Rate is 70.20%, which is 35% above median its 10-year median of 52.00 and 667.2% above the Drug Manufacturers industry median of 9.15. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For PRF Technologies (PRFX), the current 3-Year FCF Growth Rate is 70.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
